Pharmaceuticals
As a globally operating pharmaceutical company headquartered in Switzerland, we offer our pharmaceuticals and active substances worldwide. Our subsidiary Lipomed GmbH, based in Germany is responsible for the EU market.
For inquiries and orders, please contact our local partners and distributors.
Dacin® / Dacarbazine Lipomed
(Dacarbazine 200 mg, 500 mg or 1000 mg lyophilized powder)
Dacarbazine inhibits the growth of cancer cells and belongs to the pharmacotherapeutic group of alkylating agents (ATC code: L01AX04).
Dacin® / Dacarbazine Lipomed is authorised in the following countries:
Austria, Bangladesh, Cyprus, Denmark, Finland, France, Hungary, Ireland, Israel, Italy, Lebanon, Germany, Malta, Morocco, Namibia, Norway, Romania, South Africa, Switzerland and Syria
Deferiprone Lipomed
(Deferiprone 500 mg scored film-coated tablets)
Deferiprone removes excess iron from the body and belongs to the pharmacotherapeutic group of iron chelating agents (ATC code: V03AC02).
In addition to all member states of the European Union Deferiprone Lipomed is also authorised in the following countries:
Azerbaijan, Bangladesh, Iceland, Liechtenstein, Norway, Switzerland and United Kingdom
Jayempi®
(Azathioprine 10 mg/ml oral suspension)
Azathioprine (6-[(1-Methyl-4-nitro-1H-imidazole-5-yl)thio]-7H-purine) acts as an immunosuppressant by inhibiting purine synthesis and belongs to the pharmacotherapeutic group of immunosuppressants (ATC code: L04AX01).
In addition to all member states of the European Union, Jayempi® is also authorised in the following countries:
Iceland, Liechtenstein and Norway.
The distribution of Jayempi® in Germany and Austria is handled by Apocare Pharma GmbH.
Kapanol®
(Morphine sulphate pentahydrate 10 mg, 20 mg, 50 mg, 100 mg or 200 mg prolonged-release capsules)
Morphine is an alkaloid from the opium poppy (Papaver somniferum) with opiate agonistic properties and belongs to the pharmacotherapeutic group of natural opium alkaloids (ATC code: N02AA01).
Kapanol® is sold only in Switzerland by LIPOMED AG
Litak®
(Cladribine 2 mg/ml solution for injection)
Cladribine (2-chloro-2'-deoxy-β-D-adenosinum; 2-CdA) inhibits the growth of cancer cells and belongs to the pharmacotherapeutic group of purine analogues (ATC code: L01BB04).
In addition to all member states of the European Union Litak® is also authorised in the following countries:
Australia, Chile, Colombia, Ecuador, Egypt, Iceland, Israel, Jordan, Lebanon, Liechtenstein, North Macedonia, Morocco, Norway, Panama, Serbia, South Africa, Switzerland, Tunisia, Ukraine, United Arab Emirates and United Kingdom.
Myrin®
(Thalidomide 50 mg or 100 mg coated tablets)
Thalidomide affects the functioning of the immune system and of the growth of cancer cells. Thalidomide belongs to the pharmacotherapeutic group of immunosuppressants (ATC code: L04AX02). Myrin® is prescribed and dispensed in accordance with the Thalidomide Lipomed Pregnancy Prevention Programme.
Myrin® is authorised in the following countries:
Morocco, North Macedonia, Ukraine and United Kingdom
WARNING
If thalidomide comes into contact with pregnant women, it may cause serious malformations or even the death of the unborn child. Women as well as men of reproductive age may only be prescribed Myrin® under strict medical supervision and only after a risk disclosure for safe use. Myrin® may only be dispensed and taken on a special prescription in compliance with the pregnancy prevention programme. Local regulations and relevant educational materials must be strictly followed.
Thalidomide Lipomed
(Thalidomide 100 mg coated tablets)
Thalidomide affects the functioning of the immune system and of the growth of cancer cells. Thalidomide belongs to the pharmacotherapeutic group of immunosuppressants (ATC code: L04AX02). Thalidomide Lipomed is prescribed and dispensed in accordance with the Thalidomide Lipomed Pregnancy Prevention Programme.
In addition to all member states of the European Union Thalidomide Lipomed
is also authorised in the following countries:
Iceland, Liechtenstein and Norway
WARNING
If thalidomide comes into contact with pregnant women, it may cause serious malformations or even the death of the unborn child. Women as well as men of reproductive age may only be prescribed Thalidomide Lipomed under strict medical supervision and only after a risk disclosure for safe use. Thalidomide Lipomed may only be dispensed and taken on a special prescription in compliance with the pregnancy prevention programme. Local regulations and relevant educational materials must be strictly followed.
Santuril®
(Probenecid 500 mg tablets)
Probenecid increases urinary uric acid excretion and belongs to the pharmacotherapeutic group of preparations increasing uric acid excretion (ATC code: M04AB01).
Santuril® is authorised in France and Switzerland
Xaluprine®
(Mercaptopurine monohydrate 20 mg/ml oral suspension)
Mercaptopurine inhibits the growth of cancer cells and belongs to the pharmacotherapeutic group of purine analogues (ATC-Code: L01BB02).
In addition to all member states of the European Union, Xaluprine® is also authorised in the following countries:
Switzerland, Iceland, Liechtenstein and Norway.
The distribution of Xaluprine® in Germany and Austria is handled by Apocare Pharma GmbH.
Xromi®
(hydroxycarbamide 100 mg/ml oral solution)
Hydroxycarbamide, also known as hydroxyurea, is an orally active substance that inhibits cell division and belongs to the pharmacotherapeutic group of antineoplastic agents (ATC code: L01XX05). Hydroxycarbamide also increases the concentration of foetal haemoglobin (HbF).
In addition to all member states of the European Union, Xromi® is also authorised in the following countries:
Iceland, Liechtenstein and Norway.
The distribution of Xromi® in Germany and Austria is handled by Apocare Pharma GmbH.
- +41 61 702 02 00
- +41 61 702 02 20
- save_at_lipomed.com
Monday – Thursday
08.00–12.00 h
13.00–17.00 h
Friday
08.00–12.00 h
13.00–16.30 h
Outside office hours:
In the event of a serious incident involving a Lipomed medicinal product and if urgent assistance is required.